Dr. Lon Schneider discusses the development of ARIA in Phase 3 EMERGE and ENGAGE trials that led to the FDA's accelerated approval of aducanumab for the treatment of MCI Alzheimer's disease.
Show references: https://www.alzforum.org/news/research-news/aduhelm-phase-3-data-aria-common-sometimes-serious
